MGC Diagnostics Corporation

MGC Diagnostics Corporation is a US-based company specializing in advanced medical diagnostic solutions focused on cardiorespiratory health, offering innovative software and tools for pulmonary function and cardiopulmonary exercise testing. Founded in 1977 in St. Paul, US, MGC Diagnostics Corporation is engaged in providing diagnostic solutions for cardiorespiratory health. The company has undergone a recent strategic shift as it was agreed to be acquired by CAIRE Inc.

in November 2022, a move aimed at expanding CAIRE's portfolio with Non-Invasive Cardiorespiratory Diagnostic Systems. MGC Diagnostics has successfully completed three investment deals, with its latest funding round being a Public to Private transaction amounting to USD 50. 30 mn led by Altus Capital Partners, contributing to a total of USD 50. 30 mn raised.

MGC Diagnostics specializes in advanced medical diagnostic solutions primarily focused on cardiorespiratory health. Their core product offerings include the Ascent™ cardiorespiratory diagnostic software, which streamlines pulmonary function testing (PFT) and cardiopulmonary exercise testing (CPET). This software is designed to enhance workflow efficiency with an intuitive interface, comprehensive reporting, and advanced analysis tools, serving medical professionals in hospitals, university medical centers, clinics, and research organizations. MGC Diagnostics' products are recognized for their quality, accuracy, and ease of use, catering to healthcare providers addressing chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The company markets its products across various geographical regions, including North America, Europe, and parts of Asia, ensuring broad access to vital diagnostic tools for respiratory care specialists. In the most recent fiscal year, MGC Diagnostics reported a revenue of USD 40. 04 mn and an EBITDA of USD -1. 24 mn, reflecting its operations focused on the sale of medical diagnostic products and software solutions through a business-to-business transaction structure with healthcare providers and institutions.

Following the acquisition agreement with CAIRE Inc. in November 2022, MGC Diagnostics plans to leverage its resources to enhance its product offerings in the cardiorespiratory diagnostic segment. This acquisition is anticipated to facilitate entry into broader markets and expand the geographic reach of its solutions. With the recent funding of USD 50.

30 mn, the company aims to support the expansion of its product lines and enhance its operational capabilities, thereby strengthening its position in the healthcare diagnostics industry.